AbbVie Q2 Earnings Loom as Crucial Test for Skyrizi-Rinvoq Growth Thesis

What happened

AbbVie enters its July 31 Q2 report with Skyrizi and Rinvoq reportedly growing above 20%, raised earnings guidance, and a 2.62% dividend yield, leading some to urge buying before the event. However, our WAIT rating from February 2026 remains in force because the two-drug concentration (~42% of revenue) and conditional Rinvoq exclusivity until 2037 demand quarterly proof that the $34.5B immunology framework is intact. The upcoming earnings are the first major checkpoint for management’s 2026 algorithm of ~$67B revenue and ~$18.5B free cash flow, with share-capture metrics and pricing commentary acting as early warning signals. Aesthetics remains a drag, and the pending IRA negotiation on Botox adds policy risk that tempers enthusiasm. We see no reason to pre-empt the report; a clean beat with reaffirmed guidance would move us closer to an upgrade, while any cracks in the growth narrative confirm the wisdom of waiting.

Implication

A confirmed print that shows demand-led growth and sustained share capture could justify revisiting the WAIT rating, but a miss on Rinvoq or aesthetics would materially alter the investment case given the high concentration risk and looming policy headwinds.

Thesis delta

Our thesis remains unchanged: a WAIT rating pending evidence that Skyrizi and Rinvoq can independently power the post-Humira revenue algorithm. The promotional article adds no new data to alter our cautious stance; we require Q2 confirmation that the 2026 immunology framework and free cash flow guidance are on track.